Johnson & Johnson reported that subcutaneous amivantamab, a dual EGFR and MET inhibitor, achieved a 42% overall response rate in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. More than one-third of responders had complete responses, and the median duration of response was not yet reached after nearly a year of follow-up. These promising results from the Phase 1b/2 OrigAMI-4 study highlight amivantamab's potential to improve outcomes in a cancer type with limited treatment options and poor prognosis. Johnson & Johnson has submitted a supplemental application to the FDA seeking approval for this indication, with further studies ongoing.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
